SAN DIEGO & MELBOURNE, Australia, June 24, 2026
LENZ Therapeutics has significantly expanded the international commercialization strategy for its innovative presbyopia therapy by signing an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for VIZZ™ (aceclidine ophthalmic solution) 1.44% across Australia and New Zealand. The strategic collaboration grants Arrotex exclusive rights to register and commercialize the therapy in both markets while providing LENZ with an upfront licensing payment and a significant profit share of gross margin from future product sales. The agreement marks LENZ’s fifth commercial partnership outside the United States, reinforcing the company’s strategy to broaden global access to VIZZ, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, an age-related vision condition affecting nearly 1.8 billion people worldwide. The partnership combines LENZ’s ophthalmic innovation with Arrotex’s extensive commercial network and pharmaceutical expertise to accelerate patient access throughout the Asia-Pacific region.
Strategic Commercialization Partnership Expands Global Reach
The new agreement represents an important milestone in LENZ Therapeutics’ global commercialization strategy, enabling rapid expansion into two significant ophthalmology markets through one of Australia’s leading pharmaceutical companies. Under the collaboration, Arrotex Pharmaceuticals will lead regulatory registration and commercial activities for VIZZ™ across Australia and New Zealand while leveraging its extensive relationships with healthcare professionals, pharmacies, and healthcare providers.
The partnership reflects growing international demand for innovative treatments addressing presbyopia, an age-related loss of near vision that affects almost every adult over the age of 45. With its established commercial infrastructure and broad prescription medicine portfolio, Arrotex is expected to play a pivotal role in introducing this first-in-class therapy to millions of patients seeking alternatives to traditional reading glasses and corrective lenses.
VIZZ Offers Innovative Once-Daily Treatment for Presbyopia
Advertisement
VIZZ™ (aceclidine ophthalmic solution) 1.44% represents a major advancement in ophthalmology as the first FDA-approved aceclidine-based eye drop specifically developed to treat presbyopia. Designed as a once-daily, preservative-free ophthalmic solution, the therapy provides rapid near vision improvement lasting up to 10 hours through a pupil-selective mechanism that creates a pinhole effect, extending depth of focus while minimizing stimulation of the eye’s ciliary muscles.
Unlike conventional management strategies that rely on reading glasses, multifocal lenses, or contact lenses, VIZZ offers patients greater visual independence without corrective eyewear. Since receiving U.S. FDA approval and commercial launch in the United States, the therapy has demonstrated the potential to transform treatment options for adults experiencing age-related decline in near vision while addressing one of the world’s most common visual disorders.
Growing International Footprint Supports Long-Term Growth
The agreement with Arrotex Pharmaceuticals strengthens LENZ Therapeutics’ expanding international licensing network and supports its long-term objective of making VIZZ™ accessible to patients worldwide. As the company’s fifth ex-U.S. commercialization partnership, the collaboration reflects continued confidence in the product’s clinical value and commercial potential. The growing global expansion strategy is expected to accelerate adoption of innovative ophthalmic therapies while creating new revenue opportunities through strategic regional partnerships. For Arrotex, Australia’s largest diversified pharmaceutical company, the agreement enhances its branded ophthalmology portfolio with a differentiated, first-to-market treatment capable of addressing a major unmet need in vision care.
Together, the companies aim to improve quality of life for millions of adults affected by presbyopia, while advancing innovation in ophthalmology through broader international availability of this groundbreaking therapy. The collaboration also demonstrates how strategic licensing partnerships continue to drive faster commercialization of innovative pharmaceutical products across global healthcare markets, strengthening patient access to advanced eye care solutions beyond the United States.
Source: LENZ Therapeutics, Arrotex Pharmaceuticals press release
